Stephen T. Keir

15.6k citations

168 papers · 5.8k indexed · h-index 46

Molecular Biology top 2%
Oncology top 1%
Pulmonary and Respiratory Medicine top 2%
Genetics top 0.5%
Cancer Research top 2%

Co-authors: Peter J. Houghton Darell D. Bigner Malcolm A. Smith John M. Maris E. Anders Kolb C. Patrick Reynolds Henry S. Friedman Richard Görlick
Topics: Glioma Diagnosis and Treatment (40 papers)Neuroblastoma Research and Treatments (38 papers)Cancer therapeutics and mechanisms (26 papers)
Cited by: Genetics Oncology Cancer Research
Journals: Journal of Biological Chemistry Journal of Clinical Investigation Journal of Clinical Oncology
Partner nations: United States Australia China

In The Last Decade

Stephen T. Keir

159 papers receiving 5.7k citations

Peers

Countries citing papers authored by Stephen T. Keir

Since Specialization

Citations

This map shows the geographic impact of Stephen T. Keir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen T. Keir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen T. Keir more than expected).

Fields of papers citing papers by Stephen T. Keir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen T. Keir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen T. Keir. The network helps show where Stephen T. Keir may publish in the future.

Co-authorship network of co-authors of Stephen T. Keir

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen T. Keir. A scholar is included among the top collaborators of Stephen T. Keir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen T. Keir. Stephen T. Keir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma 2025 ·Molecular Cancer Therapeutics ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Noah Bell,Stephen T. Keir,Dominique Higgins,David E. Kram,Shawn Hingtgen,Aziz Sancar,Andrew Satterlee	1
2	Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells 2023 ·Neuro-Oncology ·Heng Liu,Cheng Xu,Bill H. Diplas,(unknown),(unknown),(unknown),(unknown),Roger E. McLendon,Stephen T. Keir,David M. Ashley,Yiping He,Matthew S. Waitkus	11
3	Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide 2022 ·ACS Applied Bio Materials ·Xiaoliang Yao,Dayun Yan,Li Lin,Jonathan H. Sherman,Katherine B. Peters,Stephen T. Keir,Michael Keidar	16
4	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma 2018 ·Clinical Cancer Research ·Patrick C. Gedeon,Teilo Schaller,Satish K. Chitneni,Bryan D. Choi,Chien‐Tsun Kuan,Carter M. Suryadevara,David J. Snyder,Robert J. Schmittling,(unknown),Xiuyu Cui,Patrick Healy,James E. Herndon,Roger E. McLendon,Stephen T. Keir,Gary E. Archer,Elizabeth A. Reap,Luis Sánchez-Pérez,Darell D. Bigner,John H. Sampson	38
5	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis 2016 ·Cancer Research ·Brendan Murphy,(unknown),John M. Maris,E. Anders Kolb,Richard Görlick,C. Patrick Reynolds,Min H. Kang,Stephen T. Keir,Raushan T. Kurmasheva,Igor Dvorchik,Jianrong Wu,Catherine A. Billups,(unknown),Malcolm A. Smith,Richard B. Lock,Peter J. Houghton	40
6	MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B 2016 ·Cancer Cell ·Jing Hu,Tao Sun,Hui Wang,Zhengxin Chen,Shuai Wang,Lifeng Yuan,Tingyu Liu,Hairi Li,Pingping Wang,Yukuan Feng,Qinhong Wang,Roger E. McLendon,Allan H. Friedman,Stephen T. Keir,Darell D. Bigner,(unknown),Xiang‐Dong Fu,Qi-Jing Li,Huibo Wang,Xiao‐Fan Wang	96
7	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program 2014 ·Clinical Cancer Research ·Malcolm A. Smith,C. Patrick Reynolds,Min H. Kang,E. Anders Kolb,Richard Görlick,Hernán Carol,Richard B. Lock,Stephen T. Keir,John M. Maris,Catherine A. Billups,Dmitry Lyalin,Raushan T. Kurmasheva,Peter J. Houghton	90
8	Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy 2013 ·Clinical Cancer Research ·Vidyalakshmi Chandramohan,Xuhui Bao,Stephen T. Keir,Charles N. Pegram,(unknown),Hailan Piao,Carol J. Wikstrand,Roger E. McLendon,Chien‐Tsun Kuan,Ira Pastan,Darell D. Bigner	58
9	Reversing the Warburg Effect as a Treatment for Glioblastoma 2013 ·Journal of Biological Chemistry ·Ethan Poteet,Gourav Roy Choudhury,Ali Winters,Wenjun Li,Myoung‐Gwi Ryou,Ran Liu,Lin Tang,Anuja Ghorpade,Wen Yi,Fang Yuan,Stephen T. Keir,Hai Yan,Darell D. Bigner,James W. Simpkins,Shao‐Hua Yang	84
10	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program 2010 ·Molecular Cancer Therapeutics ·Peter J. Houghton,Christopher L. Morton,Richard Görlick,Richard B. Lock,Hernán Carol,C. Patrick Reynolds,Min H. Kang,John M. Maris,Stephen T. Keir,E. Anders Kolb,(unknown),Amy Wozniak,Catherine A. Billups,Larry Rubinstein,Malcolm A. Smith	79
11	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program 2009 ·Pediatric Blood & Cancer ·Richard Görlick,E. Anders Kolb,Peter J. Houghton,Christopher L. Morton,Doris A. Phelps,Paula Schaiquevich,Clinton F. Stewart,Stephen T. Keir,Richard B. Lock,Hernán Carol,C. Patrick Reynolds,John M. Maris,Jianrong Wu,Malcolm A. Smith	26
12	Pediatric preclinical testing program (PPTP) evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886) 2008 ·Cancer Research ·Malcolm A. Smith,Christopher L. Morton,John M. Maris,Joshua Courtright,E. Anders Kolb,Richard Görlick,Hernán Carol,Richard B. Lock,Henry S. Friedman,Stephen T. Keir,Min H. Kang,C. Patrick Reynolds,Peter J. Houghton	1
13	Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454 2007 ·Molecular Cancer Therapeutics ·Peter J. Houghton,John M. Maris,Henry S. Friedman,Stephen T. Keir,Richard B. Lock,Hernán Carol,Richard Görlick,E. Anders Kolb,(unknown),C. Patrick Reynolds,Christopher L. Morton,Malcolm A. Smith	1
14	Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib 2007 ·Molecular Cancer Therapeutics ·Peter J. Houghton,John M. Maris,Joshua Courtright,Henry S. Friedman,Stephen T. Keir,Richard B. Lock,Hernán Carol,Richard Görlick,E. Anders Kolb,Nino Keshelava,C. Patrick Reynolds,Christopher L. Morton,Malcolm A. Smith	1
15	Screening for distress in patients with brain cancer using the NCCN's rapid screening measure 2007 ·Psycho-Oncology ·Stephen T. Keir,(unknown),Jonas J. Swartz,(unknown),Henry S. Friedman	71
16	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program 2007 ·Pediatric Blood & Cancer ·Peter J. Houghton,Christopher L. Morton,E. Anders Kolb,Richard B. Lock,Hernán Carol,C. Patrick Reynolds,Nino Keshelava,John M. Maris,Stephen T. Keir,Jianrong Wu,Malcolm A. Smith	98
17	Stress and intervention preferences of patients with brain tumors 2006 ·Supportive Care in Cancer ·Stephen T. Keir,Ann Bebe Guill,(unknown),Henry S. Friedman	36
18	NMDA and AMPA glutamate receptor antagonists in the treatment of human malignant glioma xenografts 2004 ·Cancer Research ·Ranjit K. Goudar,Stephen T. Keir,Darell D. Bigner,Henry S. Friedman	3
19	Therapeutic activity of the topoisomerase I inhibitor J-107088 [6- N -(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β- D -gluco pyranosyl)- 5H -indolo[2,3- a ]-pyrrolo[3,4- c ]-carbazole-5,7( 6H )-dione] against pediatric and adult central nervous system tumor xenografts 2001 ·Cancer Chemotherapy and Pharmacology ·(unknown),Stephen T. Keir,Tomoko Yoshinari,Darell D. Bigner,Henry S. Friedman	28
20	Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model 1996 ·Nuclear Medicine and Biology ·Ganesan Vaidyanathan,Henry S. Friedman,Stephen T. Keir,Michael R. Zalutsky	31

About Stephen T. Keir

Stephen T. Keir is a scholar working on Genetics, Neurology and Oncology, having authored 168 papers that have together received 5.8k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (40 papers), Neuroblastoma Research and Treatments (38 papers) and Cancer therapeutics and mechanisms (26 papers). The work is most often cited by research in Genetics (1.1k citations), Oncology (2.1k citations) and Cancer Research (972 citations). Stephen T. Keir has collaborated with scholars based in United States, Australia and China. Frequent co-authors include Peter J. Houghton, Darell D. Bigner, Malcolm A. Smith, John M. Maris, E. Anders Kolb, C. Patrick Reynolds, Henry S. Friedman, Richard Görlick, Richard B. Lock and Christopher L. Morton. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact